The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic ...
Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug ...
Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback